STOCK TITAN

Q/C Technologies owner swaps warrants for 4.98M shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Q/C Technologies, Inc. (QCLS) reported that 10% owner PharmaCyte Biotech, Inc. exchanged 851,304 Series G warrants for 4,982,272 common shares on November 18, 2026. The post-transaction positions listed were 5,152,000 common shares and 13,318,344 Series G warrants. The 5,152,000 common shares include 169,728 shares acquired as payment of Series G dividends. The exchange share amount was based on the warrants’ Black Scholes value divided by $0.3101, the common stock’s closing price on the last trading day before the agreement. No Rule 10b5-1 plan is reported.

The Form 4 also records the acquisition of 3,000 Series H preferred shares, with 3,000 listed after the transaction. The related note says PharmaCyte consented to extending their maturity from March 2, 2027 to September 2, 2027 for no additional consideration.

Insider PharmaCyte Biotech, Inc.
Role 10% Owner
Type Security Shares Price Value
In-the-Money Exercise Series G Long-Term Warrants F3, F1 851,304 $0.00 $0.00
Other Series H Convertible Preferred Stock F4, F5 3,000 $0.00 $0.00
In-the-Money Exercise Common stock F1, F2 4,982,272 $0.00 $0.00
Holdings After Transaction: Series G Long-Term Warrants — 13,318,344 warrants (Direct); Series H Convertible Preferred Stock — 3,000 shares (Direct); Common stock — 5,152,000 shares (Direct)
Holdings Before and After: Series G Long-Term Warrants, 14,169,648 to 13,318,344 warrants (Direct); Series H Convertible Preferred Stock, 0 to 3,000 shares (Direct); Common stock, 169,728 to 5,152,000 shares (Direct)
Footnotes (5)
  1. F1. On November 18, 2026, pursuant to a Consent and Warrant Exchange Agreement dated November 15, 2026 (the "Consent Agreement"), between PharmaCyte Biotech, Inc. (the "Reporting Person") and Q/C Technologies, Inc. (the "Issuer"), the Reporting Person exchanged 851,304 Series G Long-Term Warrants for 4,982,272 shares of common stock, par value $0.001 per share of the Issuer ("Common Stock"). The number of shares of Common Stock issued was determined based on the Black Scholes value of the exchanged warrants divided by $0.3101 per share, the closing price of the Common Stock on the last trading day prior to execution of the Consent Agreement.
  2. F2. Includes 169,728 shares of Common Stock acquired as payment of Series G Dividends exempt from Section 16 of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16a-9(a) promulgated thereunder.
  3. F3. Series G Long-Term Warrants are exercisable for shares of Common Stock at an exercise price of $0.3101 per share, subject to adjustment.
  4. F4. Each share of Series H Convertible Preferred Stock, with a stated value of $1,000, is convertible at the holder's election into approximately 3,225 shares of Common Stock, based on the current conversion price of $0.3101 per share, subject to adjustment.
  5. F5. On November 18, 2026, pursuant to the Consent Agreement, the Reporting Person consented to an amendment to the Certificate of Designations extending the maturity date of the Series H Preferred Shares from March 2, 2027 to September 2, 2027, for no additional consideration. Any deemed cancellation pursuant to the amendment is exempted by Rule 16b-6(d), and the cancellation also is exempt from reporting under Rule 16a-4(d)
Series G warrants exchanged 851,304 warrants November 18, 2026
Common shares received in exchange 4,982,272 shares November 18, 2026
Common shares following transaction 5,152,000 shares Includes 169,728 shares acquired as payment of Series G dividends
Series G warrants following transaction 13,318,344 warrants Position listed after the November 18, 2026 transaction
Series G warrant exercise price $0.3101 per share Subject to adjustment
Series H preferred shares following transaction 3,000 shares Position listed after the November 18, 2026 transaction
Series H preferred maturity September 2, 2027 Extended from March 2, 2027
Series G Long-Term Warrants technical
"exchanged 851,304 Series G Long-Term Warrants for 4,982,272 shares"
Black Scholes value financial
"determined based on the Black Scholes value of the exchanged warrants"
The Black–Scholes value is the theoretical fair price of a stock option calculated by the Black–Scholes mathematical model; it combines the current stock price, the option’s strike price, time until expiration, expected price swings (volatility), and interest rates to produce a single number. Investors use it like a reference sticker price: to spot mispriced options, guide trading and hedging decisions, and estimate potential risk and reward without relying on emotion or guesswork.
Series H Convertible Preferred Stock financial
"Each share of Series H Convertible Preferred Stock, with a stated value of $1,000"
Certificate of Designations regulatory
"consented to an amendment to the Certificate of Designations"
A certificate of designations is a formal legal document that spells out the specific rights and rules attached to a particular class of stock, most often preferred shares. It tells investors who gets paid first, what dividends or conversion rights exist, and any voting or liquidation priorities—like an instruction sheet that decides which shareholders get preference if a company pays out or is sold. Those terms directly affect a security’s value and risk.
Rule 16b-6(d) regulatory
"deemed cancellation pursuant to the amendment is exempted by Rule 16b-6(d)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many QCLS shares did PharmaCyte Biotech receive in the warrant exchange?

PharmaCyte Biotech, Inc. exchanged 851,304 Series G warrants for 4,982,272 common shares on November 18, 2026. The share amount was based on the warrants’ Black Scholes value divided by $0.3101, the common stock’s closing price on the last trading day before the agreement.

When does QCLS’s Series H preferred stock mature after the amendment?

The maturity date was extended to September 2, 2027, from March 2, 2027, for no additional consideration. The Series H entry lists 3,000 preferred shares after the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
PharmaCyte Biotech, Inc.

(Last)(First)(Middle)
3960 HOWARD HUGHES PARKWAY
SUITE 500

(Street)
LAS VEGAS NEVADA 89169

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Q/C TECHNOLOGIES, INC. [ QCLS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common stock11/18/2026X4,982,272(1)A$05,152,000(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Series G Long-Term Warrants(3)11/18/2026X851,304(1)05/23/202405/23/2029Common stock, par value $0.001 per share9,251,513(3)$013,318,344D
Series H Convertible Preferred Stock(4)11/18/2026J3,000(5) (4)09/02/2027Common stock, par value $0.001 per share9,674,299(4)$03,000D
Explanation of Responses:
1. On November 18, 2026, pursuant to a Consent and Warrant Exchange Agreement dated November 15, 2026 (the "Consent Agreement"), between PharmaCyte Biotech, Inc. (the "Reporting Person") and Q/C Technologies, Inc. (the "Issuer"), the Reporting Person exchanged 851,304 Series G Long-Term Warrants for 4,982,272 shares of common stock, par value $0.001 per share of the Issuer ("Common Stock"). The number of shares of Common Stock issued was determined based on the Black Scholes value of the exchanged warrants divided by $0.3101 per share, the closing price of the Common Stock on the last trading day prior to execution of the Consent Agreement.
2. Includes 169,728 shares of Common Stock acquired as payment of Series G Dividends exempt from Section 16 of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16a-9(a) promulgated thereunder.
3. Series G Long-Term Warrants are exercisable for shares of Common Stock at an exercise price of $0.3101 per share, subject to adjustment.
4. Each share of Series H Convertible Preferred Stock, with a stated value of $1,000, is convertible at the holder's election into approximately 3,225 shares of Common Stock, based on the current conversion price of $0.3101 per share, subject to adjustment.
5. On November 18, 2026, pursuant to the Consent Agreement, the Reporting Person consented to an amendment to the Certificate of Designations extending the maturity date of the Series H Preferred Shares from March 2, 2027 to September 2, 2027, for no additional consideration. Any deemed cancellation pursuant to the amendment is exempted by Rule 16b-6(d), and the cancellation also is exempt from reporting under Rule 16a-4(d)
PharmaCyte Biotech, Inc., By: /s/ Carlos A. Trujillo, Chief Financial Officer11/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading